MindMaze Therapeutics Enrolls First Patients in SwissNeuroRehab Study, Advancing At-Home Reimbursement Strategy in Europe
GENEVA, Switzerland, July 1, 2026 /PRNewswire/ — MindMaze Therapeutics Holding SA (SIX: MMTX) (MindMaze Therapeutics or the Company), a global leader in scalable precision neurotherapeutics, today announced that the SwissNeuroRehab consortium has enrolled the first patients in a…
News provided by PR Newswire.
